Top

Published in:

01-04-2015 | Research Article

Stoichiometric expression of MMP-2/TIMP-2 in benign and malignant tumours of the salivary gland

Authors: Bamidele Kolude, Akinyele Olumuyiwa Adisa, Ahmed Oluwatoyin Lawal, Bukola Folasade Adeyemi, Akindayo Olufunto Akinyamoju

Published in: Tumor Biology | Issue 4/2015

Abstract

The aim of this study was to determine the expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitors of matrix metalloproteinase 2 (TIMP-2) and the MMP-2/TIMP-2 expression ratio in salivary gland tumours (SGTs). Forty-three FFPE SGTs were prepared for antibody processing to MMP-2 and TIMP-2. Two investigators utilizing Sinicrope’s method scored the uptake of immuno-stains. Cytoplasmic staining was considered as positive. Data was analysed using SPSS version 20. The significance level was set at p < 0.05. In benign SGTs, the mean score for MMP-2 was not significantly lower than that of TIMP-2 (p = 0.37). However, the mean scores for MMP-2 stain intensity and proportion were significantly higher in malignant than benign SGTs (p = 0.01 and p = 0.02 respectively). There was no significant difference in the mean MMP-2/TIMP-2 expression ratio of the malignant SGTs according to histological grade and histogenesis (p = 0.4 and p = 0.19 respectively). The MMP-2/TIMP-2 expression ratio has a higher prognostic value than the separate expressions of MMP-2 and TIMP-2.

Johansson N, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 2000;57:5–15.CrossRefPubMed

Mook ORF, Frederiks WM, Van Noorden CJF. The role of gelatinases in colorectal cancer progression and metastasis. Biochem Biophys Acta. 2004;1705:69–89.PubMed

Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994;107:2373–9.PubMed

Stettler-Stevenson WG, Krutzsch HC, Liotta LA. TIMP-2: identification and characterization of a new member of the metalloproteinase inhibitor family. Matrix Suppl. 1992;1:299–306.

Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111–22.PubMed

Zhang X, Wang Y, Tamamoto G, Tachikawa T. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. Histopathology. 2009;55(3):250–60.CrossRefPubMed

Kayano K, Shimada T, Shinomiya T, Nakai S, Hisa Y, Aoki T, et al. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2. J Pathol. 2004;202(4):403–11.CrossRefPubMed

Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology. 2004;44(3):222–31.CrossRefPubMed

Batsakis JG, Luna MA. Histopathologic grading of salivary gland neoplasms: I. Mucoepidermoid carcinomas. Ann Otol Rhinol Laryngol. 1990;99:835–8.CrossRefPubMed

10.

Seifert G, Sobin LH. The World Health Organization’s histological classification of salivary gland tumors. A commentary on the second edition. Cancer. 1992;70(2):379–85.CrossRefPubMed

11.

Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 onco-protein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237–41.PubMed

12.

AL-Rawi NH, Al-Samarai M, Al-Kawas S, Majeed AH. Expression of matrix metalloproteinase MMP-2 and its tissue inhibitor TIMP-2 in intraoral pleomorphic adenoma and adenoid cystic carcinoma. J Int Dent Med Res. 2011;4:1–6.

13.

Matrisian L. The matrix degrading metalloproteinases. Bioassays. 1992;14:455–9.CrossRef

14.

Kinoshita T, Sato H, Okada A, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem. 1998;273:16098–103.CrossRefPubMed

15.

Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP-2 membrane type 1 metalloproteinase ‘receptor’ regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem. 1998;273:871–80.CrossRefPubMed

16.

Onisto M, Riccio MP, Scannapieco P, et al. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer. 1995;63:621–6.CrossRefPubMed

17.

Taher MG, Abdullah BH, Al-Kari LE. Expression of MMP-2 as biological markers of invasion potential in mucoepidermoid carcinoma of the oral and maxillofacial region (immunohistochemical study). Diyala J Med. 2012;3:67–72.

18.

Sierl CFM, Kubben FJGM, Ganeshl S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Lamers’ CBHW and Verspaget’ HW. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 1996;74:413–7.CrossRef

19.

Yoshizaki T, Maruyama Y, Sato H, Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001;95:44–50.CrossRefPubMed

20.

Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani S, Kagawa S. Prognostic value of matrix metalloproteinase-2 expression and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 1998;82:1359–66.CrossRefPubMed

21.

Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10:499–510.CrossRefPubMed

22.

Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387.CrossRefPubMed

23.

Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomedical Sci. 2010;17(10):1–13.

Title: Stoichiometric expression of MMP-2/TIMP-2 in benign and malignant tumours of the salivary gland
Authors: Bamidele Kolude
Akinyele Olumuyiwa Adisa
Ahmed Oluwatoyin Lawal
Bukola Folasade Adeyemi
Akindayo Olufunto Akinyamoju
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2842-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer

SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma

Clinicopathological and cellular signature of PAK1 in human bladder cancer

Epigenetic regulation of human hedgehog interacting protein in glioma cell lines and primary tumor samples

TFF3 and HER2 expression and their correlation with survival in gastric cancer

LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer